Sunlight Review
Best for: patients prioritizing publicly-disclosed compounded GLP-1 pricing ($179/mo sema or $259/mo tirz first-month) with bundled unlimited telehealth visits + free shipping, willing to verify steady-state ongoing pricing during the intake
Sunlight (sunlight.com) is a LegitScript-certified telehealth platform offering compounded GLP-1 weight-loss medications (semaglutide and tirzepatide) with publicly-disclosed first-month pricing: compounded semaglutide $179/month and compounded tirzepatide $259/month. Programs include unlimited telehealth visits and free shipping. The site uses a multi-funnel architecture (BMI-flow homepage at / and tirzepatide-flow at /t3/) common in DTC telehealth marketing. A patient testimonial verbatim references prior $1,200/month elsewhere — Sunlight positions as a cost-disrupting compounded option.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Sunlight is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Sunlight prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (first month) | compounded | $179 |
| Compounded tirzepatide (first month) | compounded | $259 |
✓ Pros
- •$179/mo compounded semaglutide and $259/mo compounded tirzepatide are publicly disclosed (first-month rate) — cost transparency advantage
- •LegitScript Certified seal verified verbatim ('Sunlight.com is a LegitScript-certified telehealth platform')
- •Unlimited telehealth visits + free shipping bundled into the flat monthly rate
- •Patient testimonial documents real-world $1,200/mo → Sunlight cost-disruption (-31 lbs in 4 months on tirzepatide)
- •Compounded-GLP-1 focused with explicit semaglutide + tirzepatide product lines
✗ Cons
- •Steady-state monthly pricing AFTER the first month is ambiguous — language verbatim is 'starts at $179 per month and tirzepatide at $259 per month for the first month' which could mean either (a) flat $179/$259 ongoing OR (b) higher steady-state with $179/$259 first-month promo. 'Each flat monthly rate includes...' suggests flat ongoing but verify during intake before committing
- •Specific legal entity name + state of incorporation NOT publicly disclosed
- •Specific partner compounding pharmacy NOT named
- •Per-state availability NOT enumerated
- •Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT addressed — compounded only
- •Multi-funnel A/B-tested marketing architecture (separate / vs /t3/ landing pages with cookie-based path persistence) is a soft signal of aggressive DTC marketing optimization rather than a clinical-medical-first platform
- •Lab work + ongoing-care touchpoints beyond the unlimited-telehealth-visits framing NOT clearly disclosed in marketing copy
Ready to start with Sunlight?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our Sunlight review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Sunlight
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Sunlight?
Starting at $179/month. See current pricing and start your free consultation.